Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HLA class I ligandome of HCT15/b2m

ABSTRACT: Mass spectrometry data of the HCT15/b2m sample, which was prepared by IP using W6/32 antibody

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Takayuki Kanaseki

PROVIDER: PXD024248 | JPOST Repository | Tue Nov 15 00:00:00 GMT 2022

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ST479_HCT15b2m_classI.raw	Raw
	ST479_HCT15b2m_classI_PEKAS-MGF.mgf	Mgf
	de%20novo%20peptides.xml	Xml

Items per page:

1 - 3 of 3

Publications

Characterization of Proteasome-Generated Spliced Peptides Detected by Mass Spectrometry.

Kato Koji K Nakatsugawa Munehide M Tokita Serina S Hirohashi Yoshihiko Y Kubo Terufumi T Tsukahara Tomohide T Murata Kenji K Chiba Hirofumi H Takahashi Hiroki H Hirano Naoto N Kanaseki Takayuki T Torigoe Toshihiko T

Journal of immunology (Baltimore, Md. : 1950) 20220527 12

CD8<sup>+</sup> T cells recognize peptides displayed by HLA class I molecules and monitor intracellular peptide pools. It is known that the proteasome splices two short peptide fragments. Recent studies using mass spectrometry (MS) and bioinformatics analysis have suggested that proteasome-generated spliced peptides (PSPs) may account for a substantial proportion of HLA class I ligands. However, the authenticity of the PSPs identified using bioinformatics approaches remain ambiguous. In this stu ...[more]

PMID: 35623660

Similar Datasets

Systematic HLA Epitope Ranking Pan Algorithm (SHERPA)

Project description:To generate high quality training data for our MHC binding and presentation prediction models, we stably transfected alleles into HLA-null, K562 to create mono-allelic cell lines. Then, we performed immunoprecipitation using W6/32 antibody and gently eluted the peptides. Finally, they were analyzed using LC-MSMS. To validate the performance of our prediction algorithms, we also processed 12 lung and colorectal tumor tissues with the same protocol.

2021-06-15 | PXD023064 | Pride

Identification of HLA class I immunopeptide from human colon tissue (Normal)

Project description:HLA Class I immunopeptides were affinity purified by W6/32 antibody and analyzed by Orbitrap Fusion Lumos with FAIMS. Personalized database which includes patient-specific somatic mutations obtained from whole exome sequencing (WES) data was used for database search. Identification results were filtered at 1% FDR thresholds by searching against a randomized decoy database using Proteome Discoverer 2.4 (Sequest HT).

2022-08-20 | PXD023804 | JPOST Repository

Identification of HLA class I immunopeptide from human colon tissue (Tumor)

2022-08-20 | PXD023805 | JPOST Repository

Pre-fractionation Extends but also Creates a Bias in the Detectable HLA Class Ι Ligandome.

Project description:HLA class Ι molecules can communicate a range of cellular alterations (mutations, changes in protein copy number, aberrant post-translational modifications, or pathogen proteins) to CD8+ T lymphocytes in the form of HLA peptide ligands. At any given moment, tens of thousands of different self and foreign HLA class Ι peptides may be presented on the cell surface by HLA class Ι complexes. Due to the enormous biochemical diversity and low abundance of each of these peptides, HLA ligandome analysis presents unique challenges. Even with advances in enrichment strategies and MS instrumentation and fragmentation, sufficient ligandome depth for identification of viral pathogens and immuno therapeutically important tumor neo-antigens is still not routinely achievable. In this study, we evaluated two pre-fractionation techniques, high-pH reversed-phase and strong cation exchange, for the complementary analyses of HLA class Ι peptide ligands. We observe that pre-fractionation substantially extends the detectable HLA class Ι ligandome but also creates an identification bias. We thus advocate a rational choice between high-pH reversed-phase or strong cation exchange pre-fractionation for deeper HLA class Ι ligandome analysis, depending on the HLA locus, allele, or peptide ligand modification in question.

| S-EPMC6456874 | biostudies-literature

Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.

Project description:The recent success of monoclonal antibody checkpoint inhibitor therapies that enhance the ability of CD8+ T cells to detect cancer-related antigenic peptides has refocused the need to fully understand the repertoire of peptides being presented to the immune system. Whilst the peptide ligandome presented by cell surface human leucocyte antigen class I (HLA-I) molecules on cancer cells has been studied extensively, the ligandome of extracellular vesicles (EVs) remains poorly defined. Here, we report the HLA-I ligandome of both the cell surface and EVs from eight breast cancer cell lines (MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, HCC 1806, HCC 1395, and HCC 1954), and additionally the melanoma cell line ESTDAB-056 and the multiple myeloma line RPMI 8226. Utilizing HLA-I immunoisolation and mass spectrometry, we detected a total of 6574 peptides from the cell surface and 2461 peptides from the EVs of the cell lines studied. Within the EV HLA-I ligandome, we identified 150 peptides derived from tumour associated antigenic proteins, of which 19 peptides have been shown to elicit T-cell responses in previous studies. Our data thus show the prevalence of clinically relevant tumour-associated antigenic peptides in the HLA-I ligandome presented on EV.

| S-EPMC10357481 | biostudies-literature

TF ChIP-seq from whole organism (ENCSR264HFB)

Project description:ChIP-seq on transgenic worms expressing lin-32-eGFP fusion proteins. The IP was performed using an anti-GFP antibody. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2024-02-27 | GSE257459 | GEO

TF ChIP-seq from whole organism (ENCSR329YGE)

Project description:ChIP-seq of transgenic worms expressing CEH-32-eGFP fusion proteins. The IP was performed using an anti-GFP antibody. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2024-02-27 | GSE257113 | GEO

TF ChIP-seq from whole organism (ENCSR533CXT)

Project description:ChIP-seq on transgenic flies expressing BEAF-32-eGFP fusion proteins. The IP was performed using an anti-GFP antibody. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2024-02-27 | GSE259206 | GEO

HLA class II ligandome of C1R BLCL cell line

Project description:HLA-DR, -DQ and -DP ligands from transfected C1R cells were isolated using LB3.1, SPVL3 and B721 antibodies respectively.

2021-08-18 | PXD025877 | Pride

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.

Project description:Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond formation. True estimation of the contribution of proteasome-spliced peptides (PSPs) to the global human leukocyte antigen (HLA) ligandome is critical. A recent study suggested that PSPs contribute up to 30% of the HLA ligandome. We performed a thorough reanalysis of the reported results using multiple computational tools and various validation steps and concluded that only a fraction of the proposed PSPs passes the quality filters. To better estimate the actual number of PSPs, we present an alternative workflow. We performed de novo sequencing of the HLA-peptide spectra and discarded all de novo sequences found in the UniProt database. We checked whether the remaining de novo sequences could match spliced peptides from human proteins. The spliced sequences were appended to the UniProt fasta file, which was searched by two search tools at a false discovery rate (FDR) of 1%. We find that 2-6% of the HLA ligandome could be explained as spliced protein fragments. The majority of these potential PSPs have good peptide-spectrum match properties and are predicted to bind the respective HLA molecules. However, it remains to be shown how many of these potential PSPs actually originate from proteasomal splicing events.

| S-EPMC6283289 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data